Ibritumomab tiuxetan Y-90 plus high-dose BEAM chemotherapy was well tolerated in older patients with non-Hodgkin's lymphoma

By  

Inpharma, Vol. 1, Iss. 1617, 2007-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma

By Kang Byung   Kim Won   Kim Chul   Jang Geundoo   Lee Sung   Choi Yoon   Lee Dae   Kim Sang   Kim Shin   Ryu Jin-Sook   Huh Jooryung   Lee Jung   Suh Cheolwon  

Investigational New Drugs, Vol. 28, Iss. 4, 2010-08 ,pp. : 516-522

Springer Publishing Company

Access to resources Recommend Favorite

Preliminary Experience with Yttrium-90-labelled Rituximab (Chimeric Anti CD-20 Antibody) in Patients with Relapsed and Refractory B Cell Non-Hodgkins Lymphoma

By  

Current Radiopharmaceuticals, Vol. 9, Iss. 2, 2016-08 ,pp. : 160-168

Bentham Science Publishers

Access to resources Recommend Favorite

New agents and approaches to the treatment of B-cell non-Hodgkin lymphoma

By Burton Jack D   Goldenberg David M  

Expert Opinion on Emerging Drugs, Vol. 15, Iss. 4, 2010-12 ,pp. : 569-583

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma

By Jamal-Hanjani Mariam   Pettengell Ruth  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 11, 2011-11 ,pp. : 1441-1448

Informa Healthcare

Access to resources Recommend Favorite